The Access to Medicine Foundation Research Hub is a central repository for evidence-based research, reports, and data regarding the pharmaceutical industry’s efforts to improve global health equity. It provides finance professionals with critical insights into how major healthcare companies manage access-related risks and opportunities in low- and middle-income countries. By centralising diverse publications, the hub serves as a key resource for evaluating corporate social responsibility and long-term sustainability within the healthcare sector.

Organisation behind the tool

The hub is developed and maintained by the Access to Medicine Foundation, an independent non-profit organisation based in the Netherlands. The Foundation is funded by various governmental and philanthropic partners and collaborates with diverse stakeholders across the global health landscape.

What the tool does

The Research Hub provides access to a comprehensive collection of evidence-based materials, including:

• Research reports, briefing papers, and articles on pharmaceutical access priorities.
• Methodologies and key findings from the Foundation’s various research programmes.
• Detailed company profiles and report cards for R&D-based pharma companies, generic manufacturers, and vaccine makers.
• Searchable archives that allow users to filter content by company, topic, disease, or region.
• Insights into specific therapeutic areas such as antimicrobial resistance and diabetes care.

Target audience

The primary users include institutional investors, pharmaceutical companies, healthcare researchers, and policymakers. It is also a valuable resource for NGOs and public health advocates focused on global health equity.

Relevance to finance professionals

Finance professionals, particularly those focused on ESG and healthcare equity, can utilise the hub for:

• Risk assessment – identifying regulatory, reputational, and operational risks associated with medicine pricing and intellectual property in emerging markets.
• ESG analysis – using standardised benchmarks and company report cards to evaluate social impact performance and ethical business practices.
• Market/commodity insights – understanding the supply chain and distribution challenges for essential medicines and vaccines in developing economies.
• Investment context – tracking long-term trends in pharmaceutical R&D and equitable access strategies to inform portfolio construction and engagement.